Catalyst
Monitor the FDA's decision on giredestrant's approval by November 30, 2026, and ongoing results from the lidERA study regarding overall survival data.
Date
June 16, 2026
Phase
N/A
Status
watch
Signal score
9.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.